Skip to main content
Clinical Trials/NL-OMON41595
NL-OMON41595
Completed
Phase 4

Immune monitoring to characterize T-cell responses of kidney transplant patients during co-stimulation blockade by belatacept - Characterizing T-cell responses during belatacept treatment

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
acute rejection
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
41
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
February 21, 2017
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • a) Male or female kidney transplant recipients.
  • b) Age \>\= 18 years.
  • c) Patients to be transplanted with a first or second kidney allograft.
  • d) Patients receiving a kidney allograft from a living donor.
  • e) Patients receiving a bloodgroup AB0\-compatible kidney transplant.
  • f) Patients receiving a non\-HLA identical kidney transplant.
  • g) Panel reactive antibodies (PRA) \<30%.
  • h) Patients must have known EBV serostatus, and that status must be positive.
  • i) Patients receiving a non\-HLA\-DR mismatched kidney transplant.

Exclusion Criteria

  • a) Recipients of a third (or higher) allograft.
  • b) Recipients of a non\-renal organ transplant.
  • c) Recipients of a kidney transplant from a deceased donor.
  • d) Recipients under the age of 18 years.
  • e) Sensitized transplant recipients (defined as a PRA of \>\=30%).
  • f) Recipients of a HLA\-identical kidney allograft.
  • g) Recipients of a bloodgroup AB0\-incompatible kidney allograft.
  • h) Recipients with a historically positive cross\-match.
  • i) Patients with a history of lymphoma.
  • j) Seronegative or unknown EBV serostatus.

Outcomes

Primary Outcomes

Not specified

Similar Trials